Immune-dependent antineoplastic effects of cisplatin plus pyridoxine in non-small-cell lung cancer.

摘要: cis-Diamminedichloroplatinum(II) (CDDP), which is mostly referred to as cisplatin, a widely used antineoplastic. The efficacy of cisplatin can be improved by combining it with the vitamin B6 precursor pyridoxine. Here, we evaluated putative synergistic interaction CDDP pyridoxine in treatment an orthotopic mouse model non-small-cell lung cancer (NSCLC). and exhibited hyperadditive therapeutic effects. However, this synergy was only observed context intact immune system disappeared when otherwise successful drug combination applied same NSCLC implanted lungs athymic mice (which lack T lymphocytes). Immunocompetent that had been cured from combined regimen plus became resistant against subcutaneous rechallenge (but not unrelated) cell line. In vitro, did cause killing cells but also elicited signs immunogenic death including endoplasmic reticulum stress response exposure calreticulin at surface cells. treated vitro protective anticancer upon their injection into immunocompetent mice. Altogether, these results suggest mediates immune-dependent antineoplastic effects NSCLC.